Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US. Prostate Cancer. 2019 Jul 9. doi: 10.1155/2019/5971615
Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarro M, Kaye JA. Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States. Prostate Cancer. 2019 Feb 11;2019:4387415. doi: 10.1155/2019/4387415
Andronis L, Oppong RA, Manga N, Senanayake E, Gopal S, Charman S, Giri R, Luckraz H. Is the Venner-PneuX endotracheal tube system a cost-effective option for post cardiac surgery care? Ann Thorac Surg. 2018 Sep;106(3):757-63. doi: 10.1016/j.athoracsur.2018.03.058
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.
Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011 Nov 1;2(4):e215-26.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.